Dermatologic adverse events of Bcr-Abl tyrosine kinase inhibitors

Abstract

Introduction. The majority of drugs used for targeted antitumor therapy are associated with dermatological toxicities. Dermatological adverse events significantly affect patient quality of life and can require the modification of treatment regimens with Bcr-Abl tyrosine kinase inhibitors.Aim. to analyze specific skin adverse events of Bcr-Abl tyrosine kinase inhibitors in accordance with their activity against the main and additional protein kinase targets.Main Findings. This article presents data on dermatological adverse events, possible mechanisms for their development, as well as a clinical picture and treatment of the most significant skin adverse events requiring the modification of therapy with Bcr-Abl tyrosine kinase inhibitors. A comparison of clinical and histological data of skin adverse reactions and the dermatological nosologies, which they imitate, is presented. Further investigation into the mechanisms of development of specific dermatological adverse events is of interest to both hematologists an dermatologists. This will contribute to a better understanding of the effect Bcr-Abl tyrosine kinase inhibitors have on skin structures and control of dermatological adverse events, as well as assist in the development of supportive oncodermatology.Conflict of interest: the authors declare no conflict of interest.Financial disclosure: the study had no sponsorship.